Stocks · News reference
Verastem Oncology has scheduled the release of its third quarter 2026 financial results and business updates for November 5, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Novocure and Verastem Oncology have entered into a clinical trial collaboration and supply agreement to evaluate the combination of Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem's KRAS G12D inhibitor, VS-7375.
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $24 price target.